Navigation Links
Sigma-Aldrich Launches Your Favorite Gene Powered by Ingenuity

Web Portal Provides Access to Dynamic Library of Life Science Research and Enables Experiment Modeling

ST. LOUIS, Jan. 27 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL) and Ingenuity Systems today launched Your Favorite Gene powered by Ingenuity, a Web-based biological search portal for exploring dynamic gene-based content ( Based on Ingenuity's extensive library of research findings, Your Favorite Gene powered by Ingenuity positions Sigma-Aldrich's life science products within a content-rich environment of relevant biological and chemical information. The Web site also provides researchers with the capability to model and evaluate prospective experiments in the context of previously published scientific literature.

The new portal is built upon Sigma-Aldrich's leading Your Favorite Gene search engine, and incorporates Ingenuity's Knowledge Base, the world's largest repository of biological and chemical networks. A dramatic departure from the prevalent static search interfaces among life science product providers, this intuitive search tool matches thousands of Sigma-Aldrich products to biological information, presented in dynamic networks.

Researchers and students can search by gene, protein, function, disease, species, tissue or pathway to access a range of previous research findings and biological information including molecular functions, cell regulation, protein domains, and metabolic and signaling pathways. From an initial search, simple navigation allows exploration of broader networks, providing insight into pathway interactions. Researchers can also model prospective experiments in Your Favorite Gene powered by Ingenuity, accessing the findings of previous studies and quickly sourcing the availability of Sigma-Aldrich products relevant to their work.

"Sigma-Aldrich is establishing itself as a destination for the life science community to understand biology and access the resources it needs to continue groundbreaking research," said Dr. David Smoller, President of Sigma-Aldrich's Research Biotech business unit. "We intend Your Favorite Gene powered by Ingenuity to serve as an information hub for researchers and students exploring diseases, functions, and gene pathways, and to match our comprehensive collection of products, kits and reagents to relevant biological information."

Ingenuity's library is comprised of information extracted from a range of leading and specialized scientific journals by a team of Ph.D.-level life scientists. Ingenuity's networks of biological and chemical relationships are manually curated, providing researchers with the most up-to-date findings related to proteins, genes, complexes, drugs, tissues, cells, and diseases of interest. Your Favorite Gene powered by Ingenuity will present select information from Ingenuity's library, with quick links to the larger repository for Ingenuity subscribers.

"Today's increasing emphasis on a systems view of biology is requiring scientists to design their experiments based on a more complete and dynamic understanding of biology," said Jake Leschly, CEO of Ingenuity. "Through Your Favorite Gene powered by Ingenuity, researchers are now able to leverage the breadth of Ingenuity's knowledge and technology to gain scientific insight and to immediately translate this into more effective experimental designs and a better selection of Sigma-Aldrich products."

Your Favorite Gene powered by Ingenuity provides streamlined access to Sigma-Aldrich's extensive portfolio of validated shRNAs, siRNAs, Prestige Antibodies and bioactive small molecule products. The Web portal is free for all researchers and students, and can be accessed at

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 36 countries and has 8,000 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at

About Ingenuity Systems: Ingenuity Systems enables researchers to model, analyze, and understand complex biological and chemical systems foundational to human health and disease. All of Ingenuity's products and services have one common goal -- to provide relevant context and understanding to life science researchers. The Ingenuity products include pathways analysis software and knowledge bases for life scientists and bioinformaticians, in addition to business solutions focused on semantic search and enterprise knowledge management infrastructure. Ingenuity was founded in 1998 and is headquartered in Redwood City, California with offices in Germany, Switzerland, France, the United Kingdom, and Japan.

Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Companies' expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Companies' operations and conditions in the markets the Companies serve. The Companies do not undertake any obligation to update these forward-looking statements.

SOURCE Sigma-Aldrich
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sigma-Aldrich Corporations 4th Quarter 2008 Earnings Conference Call
2. Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
3. Sigma-Aldrich Acquires Seppro(R) Depletion Technology From GenWay Biotech
4. Sigma-Aldrich Signs Agreement With SouthWest NanoTechnologies to Distribute SWeNT(R) Single-Wall Carbon Nanotubes
5. Sigma-Aldrich Enters Into Research Collaboration Program With D-Finitive Cell Technologies, Inc., to Develop Research Tools for Regenerative Medicine
6. Sigma-Aldrich to Present at the 19th Annual Citi Chemicals Conference Tuesday, December 2, 2008
7. Sigma-Aldrich Introduces MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA, a Superior Quality siRNA Designed for RNAi Research in Animal Models
8. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
9. Sigma-Aldrich Introduces Methylated DNA Quantification Technology for Epigenetic Research
10. Sigma-Aldrich Releases WTA2, a Transplex Whole Transcriptome Amplification Technology for Degraded RNA Samples
11. Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares.
Post Your Comments:
(Date:6/27/2016)... 2016  Global demand for enzymes is forecast ... to $7.2 billion.  This market includes enzymes used ... biofuel production, animal feed, and other markets) and ... Food and beverages will remain the largest market ... of products containing enzymes in developing regions.  These ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created 4Sight ... solutions to the healthcare market. The company's primary focus is on new product ... marketing strategies that are necessary to help companies efficiently bring their products to ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
Breaking Biology Technology:
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
(Date:6/1/2016)... YORK , June 1, 2016 ... Technology in Election Administration and Criminal Identification to Boost ... to a recently released TechSci Research report, " Global ... By Region, Competition Forecast and Opportunities, 2011 - 2021", ... 24.8 billion by 2021, on account of growing security ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
Breaking Biology News(10 mins):